Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Fate Therapeutics Inc Stock Research

FATE

2.02USD-0.06(-2.88%)Market Closed
Watchlist

Market Summary

USD2.02-0.06
Market Closed
-2.88%

FATE Stock Price

FATE RSI Chart

FATE Valuation

Market Cap

204.9M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

1.5

Price/Free Cashflow

-0.98

FATE Price/Sales (Trailing)

FATE Profitability

Return on Equity

-49.2%

Return on Assets

-37.27%

Free Cashflow Yield

-101.77%

FATE Fundamentals

FATE Revenue

Revenue Y/Y

220.3%

Revenue Q/Q

32.97%

FATE Earnings

Earnings (TTM)

-211.6M

Earnings Y/Y

30.68%

Earnings Q/Q

-179.41%

Price Action

52 Week Range

1.9923.96
(Low)(High)

Last 7 days

-18.4%

Last 30 days

-20.9%

Last 90 days

-58.9%

Trailing 12 Months

-90.5%

FATE Financial Health

Current Ratio

9

FATE Investor Care

Shares Dilution (1Y)

1.88%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for FATE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-18
Dulac Edward J III
sold
-13,210
2.8
-4,718
chief financial officer
2023-08-04
Xu Yuan
sold
-2,344
3.71
-632
-
2023-07-05
Dulac Edward J III
sold
-25,029
4.83
-5,182
chief financial officer
2023-07-05
Powl Brian T.
sold
-18,769
4.87
-3,854
chief commercial officer
2023-06-14
Xu Yuan
sold
-19,306
5.58
-3,460
-
2023-04-21
Redmile Group, LLC
bought
1,586,030
6.18
256,639
-
2023-04-20
Redmile Group, LLC
bought
119,800
5.99
20,000
-
2023-04-18
Chu Yu-Waye
sold
-16,647
6.57491
-2,532
chief medical officer
2023-04-14
Redmile Group, LLC
sold
-32,075,500
5.84
-5,492,380
-
2023-04-14
Redmile Group, LLC
bought
154,200
6.00
25,700
-

1–10 of 50

Which funds bought or sold FATE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-4.34
-574,000
2,281,000
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
86.67
57,336
159,936
-%
2023-08-22
Asset Dedication, LLC
unchanged
-
-
-
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-1.94
-102,416
462,996
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-3.34
-7,063
30,257
-%
2023-08-17
Coppell Advisory Solutions LLC
new
-
42,375
42,375
0.01%
2023-08-16
Nuveen Asset Management, LLC
added
30.89
116,312
1,374,310
-%
2023-08-15
COLONY GROUP LLC
unchanged
-
-22,000
114,000
-%
2023-08-15
BENJAMIN F. EDWARDS & COMPANY, INC.
unchanged
-
-1,000
2,000
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
24.88
24,879
605,139
-%

1–10 of 48

Latest Funds Activity

Are funds buying FATE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FATE
No. of Funds

Schedule 13G FIlings of Fate Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 10, 2023
state street corp
14.24%
13,989,432
SC 13G/A
Apr 19, 2023
redmile group, llc
14.9%
15,071,096
SC 13D/A
Mar 22, 2023
millennium management llc
1.7%
1,696,431
SC 13G
Mar 10, 2023
vanguard group inc
10.12%
9,936,042
SC 13G/A
Feb 13, 2023
capital world investors
5.8%
5,591,517
SC 13G
Feb 09, 2023
vanguard group inc
8.20%
7,972,551
SC 13G/A
Feb 03, 2023
state street corp
6.11%
5,935,459
SC 13G
Jan 06, 2023
blackrock inc.
10.0%
9,725,895
SC 13G/A
Feb 09, 2022
ark investment management llc
10.80%
10,312,167
SC 13G/A
Feb 03, 2022
blackrock inc.
7.4%
7,060,552
SC 13G/A

Recent SEC filings of Fate Therapeutics

View All Filings
Date Filed Form Type Document
Sep 01, 2023
8-K
Current Report
Aug 21, 2023
4
Insider Trading
Aug 18, 2023
144
Notice of Insider Sale Intent
Aug 08, 2023
8-K
Current Report
Aug 08, 2023
10-Q
Quarterly Report
Aug 07, 2023
4
Insider Trading
Aug 04, 2023
144
Notice of Insider Sale Intent
Jul 06, 2023
4
Insider Trading
Jul 06, 2023
4
Insider Trading
Jul 05, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Fate Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
143.9B
26.6B
4.09% 19.43%
18.04
5.41
0.75% 21.34%
94.2B
27.4B
-2.64% 21.17%
17.17
3.44
-0.48% 32.56%
37.4B
10.7B
-12.29% -20.60%
30.97
3.51
-53.67% -91.41%
37.3B
10.0B
-3.56% 28.94%
14.01
3.74
-6.23% 29.40%
MID-CAP
11.1B
1.7B
5.73% 9.84%
62.9
6.63
29.01% 1345.90%
4.3B
-
-8.76% 177.74%
-7.34
48.33
54.84% -12.96%
3.0B
-
-4.47% -19.12%
-23.53
37.44
122.90% 54.78%
1.8B
80.2M
-0.86% -51.14%
-5.62
22.95
42.17% -39.82%
SMALL-CAP
1.4B
121.2M
-17.40% -25.98%
-4.84
11.47
-70.36% -531.73%
952.5M
15.3M
-21.41% 1.70%
-5.24
62.21
1090.59% -36.57%
670.5M
1.6B
-9.19% -65.19%
-1.14
0.42
23.74% 60.24%
204.9M
-
-20.91% -90.53%
-0.97
1.5
116.83% 16.61%
120.9M
-
-9.97% -85.99%
-0.61
0.5
113.96% -15.19%
107.9M
2.1M
-8.04% -65.52%
-1.07
52.51
487.70% -8.66%
3.7M
-
-11.22% -96.54%
-0.05
3.21
- -129.46%

Fate Therapeutics News

Benzinga
NK Cell Therapy Market | Revenue Breakdown and Future Growth Potential 2030.
Benzinga,
6 hours ago
InvestorsObserver
Morrison Foerster

Returns for FATE

Cumulative Returns on FATE

-6.8%


7-Year Cumulative Returns

-32.9%


5-Year Cumulative Returns

-62.0%


3-Year Cumulative Returns

Risks for FATE

What is the probability of a big loss on FATE?

100%


Probability that Fate Therapeutics stock will be more than 20% underwater in next one year

98.1%


Probability that Fate Therapeutics stock will be more than 30% underwater in next one year.

42.7%


Probability that Fate Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does FATE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Fate Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Fate Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-100.0%-136,866,00096,300,00069,013,00068,257,00063,120,00055,846,00054,675,00048,008,00040,061,00031,434,00018,340,00013,211,00010,563,00010,680,0009,539,0008,136,0006,346,0004,740,0004,106,0004,106,000
Operating Expenses-9.6%361,217,000399,377,000404,686,000382,362,000349,838,000308,371,000272,840,000235,686,000205,883,000179,864,000159,519,000142,104,000132,607,000125,336,000111,407,00097,929,00086,099,00079,830,00071,832,00066,701,00060,349,000
  S&GA Expenses2.7%87,704,00085,433,00084,232,00079,584,00073,747,00065,564,00057,321,00050,699,00043,332,00038,667,00033,896,00030,254,00028,249,00026,016,00023,637,00021,273,00019,008,00017,554,00015,808,00014,885,00013,592,000
  R&D Expenses-12.9%273,513,000313,944,000320,454,000302,778,000276,091,000242,807,000215,519,000184,987,000162,551,000141,197,000125,623,000111,850,000104,358,00099,320,00087,770,00076,656,00067,091,00062,276,00056,024,00051,816,00046,757,000
Interest Expenses---------------1,752,0001,644,0001,673,0001,689,0001,696,0001,678,0001,627,000
Net Income9.9%-211,599,000-234,949,000-281,721,000-294,046,000-253,754,000-232,782,000-212,151,000-196,617,000-211,993,000-184,932,000-173,387,000-148,578,000-116,503,000-111,909,000-98,149,000-85,874,000-76,047,000-72,223,000-66,598,000-63,068,000-56,970,000
Net Income Margin100.0%--1.72-2.93-4.26-3.72-3.69-3.80-3.60-4.42-4.62-5.52-8.10-8.82-10.59-9.19------
Free Cashflow100.0%--241,145,000-283,774,000-290,370,000-274,757,000-257,194,000-213,574,000-147,848,000-131,425,000-47,495,000-44,161,000-49,350,000-38,765,000-99,074,000-90,570,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-7.2%5856307067498078589219851,0161,04662262665432230234020022121322083.00
  Current Assets-10.4%39243850253559959963369471380449449754020822730616518620521480.00
    Cash Equivalents11.4%47.0042.0061.0082.0055.0065.0013412977.0010616734943383.0010025071.0018319118336.00
  Net PPE-2.1%10610911010910398.0092.0075.0059.0048.0032.0021.0016.0012.0011.0010.009.008.005.004.003.00
  Current Liabilities-8.1%45.0049.0011410492.0078.0081.0092.0010695.0086.0054.0045.0025.0028.0041.0029.0029.0027.0023.0016.00
    LT Debt, Current----------------14.005.004.002.003.002.00
    LT Debt, Non Current-----------------9.0011.0012.0012.0013.00
Shareholder's Equity-8.3%43847748451858063367973075279038442447421924526812814616017452.00
  Retained Earnings-4.9%-1,122-1,069-1,050-994-910-834-769-700-657-602-556-503-445-417-383-355-328-305-285-269-252
  Additional Paid-In Capital0.8%1,5611,5481,5361,5161,4951,4711,4491,4311,4091,392941928919636628623456451446443304
Shares Outstanding0.3%99.0098.0097.0097.0097.0096.0096.0095.0094.0093.0088.0081.0078.0076.0068.0067.0065.0065.0056.0053.0053.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations11.6%-187-212-248-243-221-200-162-113-110-39.65-39.23-44.10-33.20-92.35-83.17-68.66-52.38-43.59-38.65-38.35-44.56
  Share Based Compensation-10.9%63.0070.0079.0074.0068.0061.0054.0049.0043.0037.0031.0027.0023.0020.0017.0015.0012.009.006.005.005.00
Cashflow From Investing-3.9%176183167185182141-324-561-693-656-161-105-15.14-142-157-30.55-53.5652.00-0.46-3.64-3.28
Cashflow From Financing-50.6%3.007.009.0011.0018.0018.0045345544871928326442515015016614114214118253.00

FATE Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Collaboration revenue$ 933$ 18,549$ 59,913$ 36,963
Type of Revenue [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:    
Research and development$ 40,876$ 81,307$ 106,505$ 153,446
General and administrative22,62220,35144,56541,093
Total operating expenses63,498101,658151,070194,539
Loss from operations(62,565)(83,109)(91,157)(157,576)
Other income:    
Interest income4,3817578,0751,175
Change in fair value of stock price appreciation milestones3935,8812,11114,240
Other income5,0363669,335366
Total other income9,8107,00419,52115,781
Net loss(52,755)(76,105)(71,636)(141,795)
Other comprehensive income (loss):    
Unrealized gain (loss) on available-for-sale securities, net59(531)1,267(2,619)
Comprehensive loss$ (52,696)$ (76,636)$ (70,369)$ (144,414)
Net loss per common share, basic$ (0.54)$ (0.79)$ (0.73)$ (1.47)
Net loss per common share, diluted$ (0.54)$ (0.79)$ (0.73)$ (1.47)
Weighted-average common shares used to compute, basic net loss per share98,400,35596,704,41398,228,47696,524,968
Weighted-average common shares used to compute diluted net loss per share98,400,35596,704,41398,228,47696,524,968

FATE Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 46,802$ 61,333
Accounts receivable2,83338,480
Short-term investments and related maturity receivables331,133374,894
Prepaid expenses and other current assets11,41427,367
Total current assets392,182502,074
Long-term investments7,2914,942
Property and equipment, net106,331110,020
Operating lease right-of-use assets63,74366,069
Restricted cash15,17715,227
Collaboration contract assets07,196
Other assets3333
Total assets584,757705,561
Current liabilities:  
Accounts payable7,5068,265
Accrued expenses29,46953,932
CIRM award liability, current portion04,000
Deferred revenue1,92942,226
Operating lease liabilities, current portion5,7865,628
Total current liabilities44,690114,051
Operating lease liabilities, net of current portion100,562103,710
Stock price appreciation milestones1,7503,861
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; authorized shares-5,000,000 at June 30, 2023 and December 31, 2022; Class A Convertible Preferred shares issued and outstanding-2,761,108 at June 30, 2023 and 2,794,549 December 31, 202233
Common stock, $0.001 par value; authorized shares-250,000,000 at June 30, 2023 and December 31, 2022; issued and outstanding-98,522,718 at June 30, 2023 and 97,294,917 at December 31, 20229997
Additional paid-in capital1,560,6801,536,497
Accumulated other comprehensive loss(587)(1,854)
Accumulated deficit(1,122,440)(1,050,804)
Total stockholders’ equity437,755483,939
Total liabilities and stockholders’ equity$ 584,757$ 705,561
J. Scott Wolchko
450
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.